Lunch presentation at DNB
Corporate presentation by Jakob Lindberg, CEO, Oncopeptides AB, at DNB 25 September 2018.
Presentations
Presentation at 23rd Congress of The European Hematology Association (EHA)
The updated phase II-data show a clinical data set with an Overall Response Rate (ORR) of 32.1% and a Clinical Benefit Rate (CBR) of 39.3% with Ygalo® in relapsed/refractory multiple myeloma patients ...
Jefferies Health Care conference, New York – Presentation
Oncopeptides CEO Jakob Lindberg held a presentation at Jefferies Healthcare Conference in New York June 7.
Jakob Lindberg, CEO, is interviewed in Di tv
Oncopeptides CEO Jakob Lindberg interviewed at DI Börsmorgon (Di tv) about the Q1 Interim report and the future, May 17, 2018.
Carnegie Healthcare Seminar 2018 – presentation
Oncopeptides CEO Jakob Lindberg held a presentation at Carnegie Healthcare Seminar on March 14.
SCF Life Science Seminarium – presentation
Oncopeptides CEO Jakob Lindberg held a presentation at Stockholm Corporate Finance Live Science Seminarium March 7. Click here to view the recorded presentation.
ABGSC Orphan Drug Day 2018 – Presentation
Oncopeptides presentation at the ABG Office in Stockholm, Sweden
DNB Nordic Healthcare Conference 2017 – Oslo
Oncopeptides' presentation at DNB in Oslo, 14 December
ASH summary Webcast
Oncopeptides had a press conference on December 13. The conference was recorded. Click here to view the Webcast.
59th ASH Annual Meeting & Exposition – Posters
Horizon Poster (9 Dec 2017) and O-12-M1 Poster (10 Dec 2017)
Carnegie Healthcare Day in New York – presentation
Oncopeptides presentation at Carnegie, New York, 5 December 2017.